Daiichi Sankyo Uses Ranbaxy For Entrée Into Mexico Market
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo plans to use its ownership of India's Ranbaxy Laboratories to sell the Japanese company's drugs in Mexico
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.